PH+ mixed phenotype acute leukemia (MPAL)

Clinical trials for PH+ mixed phenotype acute leukemia (MPAL) explained in plain language.

Never miss a new study

Get alerted when new PH+ mixed phenotype acute leukemia (MPAL) trials appear

Sign up with your email to follow new studies for PH+ mixed phenotype acute leukemia (MPAL), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Terminated 1

New drug combo for kids with resistant leukemia shows early promise but study halted

Disease control Stopped early

This study tested a targeted cancer drug called ponatinib combined with standard chemotherapy in children and young adults up to age 21 with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) that had come back or stopped responding to other treatments. The g…

Matched conditions: PH+ MIXED PHENOTYPE ACUTE LEUKEMIA (MPAL)

Phase 1/2 • Sponsor: Takeda • Aim: Disease control

Last updated Jun 27, 2026 07:52 UTC

PH+ mixed phenotype acute leukemia (MPAL)

Get alerted when new PH+ mixed phenotype acute leukemia (MPAL) trials appear

New drug combo for kids with resistant leukemia shows early promise but study halted